Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis

[1]  I. Durieu,et al.  Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta‐Analysis , 2020, Arthritis care & research.

[2]  T. Takeuchi,et al.  Body mass index associates with disease relapse in patients with giant cell arteritis , 2019, International journal of rheumatic diseases.

[3]  D. Bailey,et al.  Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis: A Prospective, Double‐Blind, Cross‐Sectional Study , 2019, Arthritis & rheumatology.

[4]  F. Martínez-Valle,et al.  Risk of ischaemic events at giant cell arteritis diagnosis according to PET/CT findings , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  D. Mariano-Goulart,et al.  Diagnostic performance of 18F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy , 2019, Annals of Nuclear Medicine.

[6]  A. Aouba,et al.  Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis , 2019, The Journal of Rheumatology.

[7]  P. Giorgi Rossi,et al.  Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study , 2018, Rheumatology.

[8]  P. Bartenstein,et al.  Diagnostic accuracy of positron emission tomography for assessment of disease activity in large vessel vasculitis , 2018, International journal of rheumatic diseases.

[9]  J. Braun,et al.  The role of 18F-FDG positron emission tomography for the diagnosis of vasculitides. , 2018, Clinical and experimental rheumatology.

[10]  C. Baldini,et al.  One year in review 2018: systemic vasculitis. , 2018, Clinical and experimental rheumatology.

[11]  Eric L Matteson,et al.  Large-vessel giant cell arteritis: diagnosis, monitoring and management , 2018, Rheumatology.

[12]  A. Iagnocco,et al.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice , 2018, Annals of the rheumatic diseases.

[13]  M. Aschwanden,et al.  [18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis—lessons from a vasculitis clinic , 2017, European heart journal cardiovascular Imaging.

[14]  A. Aouba,et al.  Giant-cell arteritis without cranial manifestations , 2016, Medicine.

[15]  L. Cimino,et al.  Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy , 2016, Medicine.

[16]  E. Matteson,et al.  Large-vessel giant cell arteritis: a cohort study. , 2015, Rheumatology.

[17]  T. Kano,et al.  Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT , 2014, Rheumatology International.

[18]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[19]  L. Mortelmans,et al.  Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. , 2006, Arthritis and rheumatism.

[20]  F. Strutz,et al.  Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  A. Stanson,et al.  Disease pattern in cranial and large-vessel giant cell arteritis. , 1999, Arthritis and rheumatism.

[22]  Bouallègue,et al.  Diagnostic performance of 18 F ‐ FDG PET ‐ CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy , 2019 .

[23]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.